Portfolio company
FoRx Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
2 investors
Sectors
About
The company develops oral small molecule drugs targeting DNA replication stress for patients with treatment-resistant cancers.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Fore Bio
This biotechnology company develops precision oncology therapies and small-molecule inhibitors for patients with unaddressed tumour mutations and hard-to-treat cancers.
iOnctura
The company develops precision small-molecule medicines to treat patients with neglected and hard-to-treat solid tumours and cancers.
ARase Therapeutics
This company develops small molecule drugs targeting ADP-ribose hydrolases for patients with various forms of cancer.
Artios Pharma Limited
The company develops DNA damage response inhibitors for patients with solid tumours to overcome cancer cell survival and treatment resistance.
THERAtRAME
The company develops small molecule inhibitors targeting tRNA epitranscriptomics to treat resistant and immune-refractory cancers for patients with limited therapeutic options.
Aprea Therapeutics
This company develops targeted cancer therapies for patients with biomarker-defined tumours and DNA damage response pathway defects.
Azeria Therapeutics
The company develops small molecule drugs targeting pioneer factors to treat hormone-resistant breast and prostate cancer patients.
tolremo
This company develops small molecule drugs to prevent non-genetic resistance in cancer patients receiving targeted therapies.